People with ANCA-associated vasculitis (AAV) patients whoo have low blood levels of sulfatides, a type of fatty molecule, are significantly more likely to have future kidney failure, a single-center study in South Korea indicates. The predictive potential of blood sulfatide levels was independent of direct associations with kidney involvement…
Eosinophilic granulomatosis with polyangiitis (EGPA) patients treated at private practices in the U.S. have high disease burden associated with multiple symptoms and simultaneous health conditions, a study showed, mirroring findings reported for patients treated at academic settings. Patients treated in private practice demonstrated variable responses to standard treatments, with some patients…
Most children with ANCA-associated vasculitis (AAV) and kidney involvement at diagnosis will exhibit inactive kidney disease after one year, and more than two in five will show evidence of permanent kidney damage, according to data from an international registry study. A glomerular filtration rate (eGFR) — a standard measure…
A reduced glucocorticoid dosing regimen for inducing disease remission in people with ANCA-associated vasculitis (AAV) may be associated with a higher risk of poor disease outcomes in those with severe disease, compared with the standard-dose regimen. That’s according to a real-world study in France and Luxembourg that involved people…
Eosinophilic granulomatosis with polyangiitis (EGPA) should be considered in people with uncontrolled severe asthma and high blood levels of immune cells called eosinophils — a hallmark of the autoimmune disease — according to the findings of a study from Singapore. This rare type of ANCA-associated vasculitis (AAV) was…
Most children with granulomatosis with polyangiitis (GPA) have respiratory manifestations including cough and shortness of breath at diagnosis, and these frequently persist or relapse, according to a study in the U.S. involving 13 pediatric patients. Lung abnormalities were detected in nearly all children with available imaging data at diagnosis…
People with ANCA-associated vasculitis (AAV) have a higher frequency of thyroid diseases, that is, those that affect the hormone-production function of the thyroid gland, than the general population, a study in China suggests. Being female, having coronary artery disease, which is marked by reduced blood flow in the arteries…
Fasenra (benralizumab) has been granted approval in the European Union as an add-on treatment for adults with relapsing or treatment-resistant eosinophilic granulomatosis with polyangiitis, or EGPA, a rare type of ANCA-associated vasculitis (AAV). The clearance of Fasenra, “with its convenient, single-monthly injection is a positive step forward…
Alivexis’ experimental oral therapy MOD06051, designed to suppress an underlying mechanism of ANCA-associated vasculitis (AAV), eased blood vessel inflammation and tissue damage in a rat model of the disease, a study from Japan found. In lab-grown human and rat cells, the therapy was shown to block the activity…
People with ANCA-associated vasculitis (AAV) have a higher risk of cardiovascular diseases and related mortality than people without the disease, according to a systematic review and meta-analysis of published studies. For example, the risk of venous thromboembolism, a blood clot that develops in a vein, was three times higher…
Get regular updates to your inbox.